Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-24-010095
Filing Date
2024-07-25
Accepted
2024-07-25 06:01:40
Documents
72
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 6-K argx-20240630x6k.htm 6-K 36082
2 EX-99.1 argx-20240630xex99d1.htm EX-99.1 161367
3 EX-99.2 argx-20240630xex99d2.htm   iXBRL EX-99.2 1132964
4 GRAPHIC argx-20240630xex99d1001.jpg GRAPHIC 3320
  Complete submission text file 0001558370-24-010095.txt   4724066

Data Files

Seq Description Document Type Size
5 EX-101.SCH argx-20240630.xsd EX-101.SCH 54984
6 EX-101.CAL argx-20240630_cal.xml EX-101.CAL 68822
7 EX-101.DEF argx-20240630_def.xml EX-101.DEF 107601
8 EX-101.LAB argx-20240630_lab.xml EX-101.LAB 341035
9 EX-101.PRE argx-20240630_pre.xml EX-101.PRE 226965
75 EXTRACTED XBRL INSTANCE DOCUMENT argx-20240630xex99d2_htm.xml XML 735490
Mailing Address INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE C9 B-9052
Business Address INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE C9 B-9052 32 (9) 310 34 00
ARGENX SE (Filer) CIK: 0001697862 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38097 | Film No.: 241139620
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)